Medicine & Life Sciences
Sarcoma
100%
regorafenib
40%
Gastrointestinal Stromal Tumors
39%
Progression-Free Survival
37%
Liposarcoma
36%
Neoplasms
32%
pazopanib
30%
Aggressive Fibromatosis
26%
Hemangiosarcoma
24%
Placebos
24%
Therapeutics
24%
Leiomyosarcoma
22%
gemcitabine
21%
Sunitinib
19%
olaratumab
19%
TH 302
18%
Survival
18%
Imatinib Mesylate
18%
selinexor
18%
Synovial Sarcoma
17%
Safety
16%
Docetaxel
16%
Patient Reported Outcome Measures
16%
pembrolizumab
14%
Chordoma
14%
Ewing's Sarcoma
13%
Response Evaluation Criteria in Solid Tumors
13%
Confidence Intervals
11%
MORAb-004
10%
ribonucleotide reductase M2
10%
Quality of Life
10%
Prostatic Neoplasms
10%
Doxorubicin
10%
Myxoid Liposarcoma
9%
EPZ-6438
9%
Osteosarcoma
9%
TRC105
9%
Bone and Bones
9%
Langerhans Cell Sarcoma
9%
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
9%
1 alpha-hydroxyergocalciferol
8%
sulindac sulfone
8%
perillyl alcohol
8%
Drug Therapy
8%
Follicular Dendritic Cell Sarcoma
8%
Mutation
8%
atezolizumab
7%
Clinical Trials
7%
Heavy Ion Radiotherapy
7%
Esophagus
7%